A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF AEROVANC FOR THE TREATMENT OF PERSISTANT METHICILLIN-RESISTANT Staphylococcus aureus LUNG INFECTION IN CYSTIC FIBROSIS PATIENTS; SAV005-04

A PHASE III  RANDOMIZED  DOUBLE-BLIND  PLACEBO-CONTROLLED STUDY OF AEROVANC FOR THE TREATMENT OF PERSISTANT METHICILLIN-RESISTANT Staphylococcus aureus LUNG INFECTION IN CYSTIC FIBROSIS PATIENTS; SAV005-04

Brief description of study

TBD

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    CF, lung, MRSA
  • Age: - 99 Years
  • Gender: All
Updated on 30 Jan 2020. Study ID: 828169

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center